These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 29360813)
21. Severe vitamin D deficiency associated with BRAF-mutated melanoma. Fearfield L; Nobbs J; Petruckevitch A; Harland C Br J Dermatol; 2019 Dec; 181(6):1343. PubMed ID: 31381132 [No Abstract] [Full Text] [Related]
22. Multiparametric analysis of cell-free DNA in melanoma patients. Salvianti F; Pinzani P; Verderio P; Ciniselli CM; Massi D; De Giorgi V; Grazzini M; Pazzagli M; Orlando C PLoS One; 2012; 7(11):e49843. PubMed ID: 23209607 [TBL] [Abstract][Full Text] [Related]
23. MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma. Nakahara S; Fukushima S; Okada E; Morinaga J; Kubo Y; Tokuzumi A; Matsumoto S; Tsuruta-Kadohisa M; Kimura T; Kuriyama H; Miyashita A; Kajihara I; Jinnin M; Ihn H J Dermatol Sci; 2020 Jan; 97(1):77-79. PubMed ID: 31843231 [No Abstract] [Full Text] [Related]
24. Circulating miRNA expression analysis reveals new potential biomarkers for human cutaneous melanoma staging. Sánchez-Sendra B; García-Giménez JL; González-Muñoz JF; Navarro L; Murgui A; Terrádez L; Pinazo I; Martin JM; Monteagudo C J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):e126-e129. PubMed ID: 31710393 [No Abstract] [Full Text] [Related]
25. Circulating cell-free microRNAs in cutaneous melanoma staging and recurrence or survival prognosis. Polini B; Carpi S; Romanini A; Breschi MC; Nieri P; Podestà A Pigment Cell Melanoma Res; 2019 Jul; 32(4):486-499. PubMed ID: 30481404 [TBL] [Abstract][Full Text] [Related]
26. Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay. Blokzijl A; Chen LE; Gustafsdottir SM; Vuu J; Ullenhag G; Kämpe O; Landegren U; Kamali-Moghaddam M; Hedstrand H PLoS One; 2016; 11(4):e0154214. PubMed ID: 27110718 [TBL] [Abstract][Full Text] [Related]
27. Diversity of circulating tumor cells in peripheral blood: Detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis. Kiniwa Y; Nakamura K; Mikoshiba A; Akiyama Y; Morimoto A; Okuyama R J Dermatol Sci; 2018 May; 90(2):211-213. PubMed ID: 29426605 [No Abstract] [Full Text] [Related]
28. New prognostic factors and developing therapy of cutaneous melanoma. Vihinen PP; Pyrhönen SO; Kähäri VM Ann Med; 2003; 35(2):66-78. PubMed ID: 12795336 [TBL] [Abstract][Full Text] [Related]
29. A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma. Jakub JW; Grotz TE; Jordan P; Hunter E; Pittelkow M; Ramadass A; Akoulitchev A; Markovic S Melanoma Res; 2015 Oct; 25(5):406-11. PubMed ID: 26225582 [TBL] [Abstract][Full Text] [Related]
30. HOTAIR role in melanoma progression and its identification in the blood of patients with advanced disease. Cantile M; Scognamiglio G; Marra L; Aquino G; Botti C; Falcone MR; Malzone MG; Liguori G; Di Bonito M; Franco R; Ascierto PA; Botti G J Cell Physiol; 2017 Dec; 232(12):3422-3432. PubMed ID: 28067428 [TBL] [Abstract][Full Text] [Related]
31. [Acral lentiginous melanoma: a slow growing tumor of the second finger]. Cellier M; Sirvain S; Fraisse T Presse Med; 2010 Oct; 39(10):1100-2. PubMed ID: 20630700 [No Abstract] [Full Text] [Related]
32. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Huang SK; Hoon DS Mol Oncol; 2016 Mar; 10(3):450-63. PubMed ID: 26778792 [TBL] [Abstract][Full Text] [Related]
33. Quantitative analysis of the BRAF Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. Wang TS; Johnson TM; Cascade PN; Redman BG; Sondak VK; Schwartz JL J Am Acad Dermatol; 2004 Sep; 51(3):399-405. PubMed ID: 15337983 [TBL] [Abstract][Full Text] [Related]
35. A defined region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma. Herbst RA; Larson A; Weiss J; Cavenee WK; Hampton GM; Arden KC Cancer Res; 1995 Jun; 55(12):2494-6. PubMed ID: 7780954 [TBL] [Abstract][Full Text] [Related]
36. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333 [TBL] [Abstract][Full Text] [Related]
37. Glypican 6 is a putative biomarker for metastatic progression of cutaneous melanoma. Li Y; Li M; Shats I; Krahn JM; Flake GP; Umbach DM; Li X; Li L PLoS One; 2019; 14(6):e0218067. PubMed ID: 31199813 [TBL] [Abstract][Full Text] [Related]